Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues

International Journal of Cancer

Volumn 97, Issue 1, 2002, Pages 129-132

  Friis, Sren ^a   Nielsen, Gunnar Lauge ^b,c   Mellemkjr, Lene ^a   McLaughlin, Joseph K ^d,e   Thulstrup, Ane Marie ^b   Blot, William J ^d,e   Lipworth, Loren ^d,e   Vilstrup, Hendrik ^b   Olsen, Jrgen H ^a  

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Breast cancer; Chemosensitivity; CYP3A4; Docetaxel

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DOCETAXEL; EPIRUBICIN; ESTROGEN RECEPTOR; MESSENGER RNA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DRUG INACTIVATION; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; FEMALE; HUMANS; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PACLITAXEL; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036132097     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1568     Document Type: Article

References (17)

1. Phase II evaluation of Taxotere (RP56976 NSC 628503) as initial chemotherapy for metastatic breast cancer
2. Experience with docetaxel in breast cancer
3. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer
4. Phase II evaluation of Taxotere (RP56976) as chemotherapy for anthracycline refractory metastatic breast cancer
5. Studies with RP 56976 (taxotere): A semisynthetic analogue of taxol
6. Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers
7. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes
8. Partial synthesis of major human metabolites of decetaxel
9. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction
10. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice
11. Use of the nuclear receptor PXR to predict drug interactions
12. Docetaxel in patients with anthracycline-resistant advanced breast cancer
13. 2 in patients with metastatic breast cancer according to the status of anthracycline resistance
14. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans
15. Differential activation of cyclophosphamide and ifosphamide by cytochrome P450 2B and 3A in human liver microsomes
16. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance
17. Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2EI in human liver